Biogen 2015 Revenues Increase 11% to $10.8 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Biogen (BIIB) Pushes Higher Following EPS
January 27, 2016 11:55 AM ESTBiogen (NASDAQ: BIIB) is pushing to the highs of the session following strong earnings and a solid outlook. Shares are now up 7.9%
... MoreBiogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook
January 27, 2016 8:23 AM ESTBiogen (NASDAQ: BIIB) is trading up 4.9% in pre-open trading Wednesday following strong fourth quarter results and solid guidance.
Biogen reported Q4 EPS of $4.50, $0.42 better than the analyst estimate of $4.08. Revenue for the quarter rose 8% to $2.84 billion versus the consensus estimate of $2.71 billion.
TECFIDERA... More
Biogen (BIIB) Tops Q4 EPS by 42c; Guides In-Line
January 27, 2016 7:16 AM ESTBiogen (NASDAQ: BIIB) reported Q4 EPS of $4.50, $0.42 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.84 billion versus the consensus estimate of $2.71 billion.
GUIDANCE:
Biogen sees FY2016 EPS of $18.30-$18.60, versus the consensus of $18.45. Biogen sees FY2016 revenue of $11.1-11.3 billion, versus the consensus of $11.29 billion.
We saw solid performance in our industry leading multiple sclerosis portfolio and strong... More

